Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study
Essential thrombocythemia (ET) is the most “benign” of the myeloproliferative neoplasms (MPNs), with a near-normal expected life span [1,2]. The median age at diagnosis is approximately 60 years, but a substantial proportion of patients with ET are younger than 60 years at diagnosis. Furthermore, the life expectancy in the general popula tion has progressively improved and reached a point where individuals aged 65 years have an average life expectancy of around 20 years in developed countries. Therefore risks or side effects associated with ET treatments are especially pertinent.
Source: Leukemia Research - Category: Hematology Authors: Birgeg ård Gunnar, Folkvaljon Folke, Garmo Hans, Holmberg Lars, Besses Carlos, Griesshammer Martin, Gugliotta Luigi, Wu Jinyang, Achenbach Heinrich, Kiladjian Jean-Jacques, N. Harrison Claire Tags: Research paper Source Type: research
More News: Cancer | Cancer & Oncology | Hematology | Leukemia | Myeloproliferative Disorders | Study